ArticleBMC public health2014
Annual public health and economic benefits of seasonal influenza vaccination: a European estimate.
Article in BMC public health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 4 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Quadrivalent Vaccines for the Immunization of Adults against Influenza: A Systematic Review of Randomized Controlled Trials.International journal of environmental research and public health · 2022Pooled it
- The economic burden of influenza among adults aged 18 to 64: A systematic literature review.Influenza and other respiratory viruses · 2022Pooled it
- The Value(s) of Vaccination: Building the Scientific Evidence According to a Value-Based Healthcare Approach.Frontiers in public health · 2022Pooled it
- A systematic review of economic evaluations of seasonal influenza vaccination for the elderly population in the European Union.BMJ open · 2017Pooled it
- Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study.Drug safety · 2018Trial
- Budget impact analysis of implementing point-of-care molecular testing for influenza A&B and RSV in Saudi older adult patients across hospital and home-care settings.Health economics review · 2026Article
- Disease burden of influenza in Spain: A five-season study (2015-2020).Human vaccines & immunotherapeutics · 2025Article
- Factors Influencing Influenza Vaccination: A Survey-Based Cross-Sectional Study in the City of Syracuse, Italy.Journal of community health · 2025Article
- Decreased risk of chronic fatigue syndrome following influenza vaccine: a 20-year population-based retrospective study.Journal of translational medicine · 2025Article
- Risk perception and factors associated with the acceptance of smallpox vaccine against monkeypox among healthcare and healthcare support workers in Northeastern Nigeria.The Pan African medical journal · 2025Article
- Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines.NPJ vaccines · 2024Article
- Article
- Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives.BMC public health · 2024Article
- The Role and Value of Professional Rapid Testing of Acute Respiratory Infections (ARIs) in Europe: A Special Focus on the Czech Republic, Poland, and Romania.Diagnostics (Basel, Switzerland) · 2024Review
- Intramuscular vs. Subcutaneous: Rethinking Influenza Vaccination Strategy in Japan.JMA journal · 2024Article
- Understanding the gap between guidelines and influenza vaccination coverage in people with diabetes: a scoping review.Frontiers in public health · 2024Article
- Article
- Vaccination practices and knowledge among adults with hemoglobinopathies in Greece: a nationwide survey.Therapeutic advances in vaccines and immunotherapy · 2024Article
- Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model.PharmacoEconomics · 2023Article
- Influenza vaccination uptake among at-risk patients in Switzerland-The potential of national claims data for surveillance.Influenza and other respiratory viruses · 2023Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaccination is currently the most effective means of preventing influenza infection. Yet evidence of vaccine performance, and the impact and value of seasonal influenza vaccination across risk groups and between seasons, continue to generate much discussion. Moreover, vaccination coverage is below recommended levels.
methodsA model was generated to assess the annual public health benefits and economic importance of influenza vaccination in 5 WHO recommended vaccination target groups (children 6 - 23 months of age; persons with underlying chronic health conditions; pregnant women; health care workers; and, the elderly, 65 years of age) in 27 countries of the European Union. Model estimations were based on standard calculation methods, conservative assumptions, age-based and country-specific data.
resultsOut of approximately 180 million Europeans for whom influenza vaccination is recommended, only about 80 million persons are vaccinated. Seasonal influenza vaccination currently prevents an annual average of between 1.6 million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths. To reach the 75% vaccination coverage target set by the EU Council Recommendation in 2009, an additional 57.4 million person would need to be vaccinated in the elderly and other risk groups. By achieving the 75% target rate set in EU-27 countries, average annual influenza- related events averted would increase from current levels to an additional +1.6 to +1.7 million cases, +23,800 to +31,400 hospitalization, +9,800 to +14,300 deaths, +678,500 to +767,800 physician visits, and +883,800 to +1,015,100 lost days of work yearly. Influenza-related costs averted because of vaccination would increase by an additional + €190 to + €226 million yearly, in vaccination target groups.
conclusionsFull implementation of current influenza vaccination recommendations of 75% vaccination coverage rate (VCR) in Europe by the 2014-2015 influenza season could immediately reduce an important public health and economic burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.